Qiagen NV (QGEN)
43.26
+0.62
(+1.45%)
USD |
NYSE |
May 31, 16:00
43.29
+0.03
(+0.07%)
After-Hours: 20:00
Qiagen Research and Development Expense (Quarterly): 51.33M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 51.33M |
| December 31, 2023 | 45.97M |
| September 30, 2023 | 47.93M |
| June 30, 2023 | 49.89M |
| March 31, 2023 | 54.72M |
| December 31, 2022 | 44.72M |
| September 30, 2022 | 48.87M |
| June 30, 2022 | 49.90M |
| March 31, 2022 | 46.38M |
| December 31, 2021 | 42.11M |
| September 30, 2021 | 48.27M |
| June 30, 2021 | 52.15M |
| March 31, 2021 | 47.43M |
| December 31, 2020 | 46.34M |
| September 30, 2020 | 36.10M |
| June 30, 2020 | 31.82M |
| March 31, 2020 | 34.81M |
| December 31, 2019 | 33.99M |
| September 30, 2019 | 41.84M |
| June 30, 2019 | 40.83M |
| March 31, 2019 | 40.79M |
| December 31, 2018 | 40.67M |
| September 30, 2018 | 42.03M |
| June 30, 2018 | 39.63M |
| March 31, 2018 | 39.52M |
| Date | Value |
|---|---|
| December 31, 2017 | 40.94M |
| September 30, 2017 | 38.30M |
| June 30, 2017 | 37.90M |
| March 31, 2017 | 36.94M |
| December 31, 2016 | 32.22M |
| September 30, 2016 | 36.04M |
| June 30, 2016 | 42.01M |
| March 31, 2016 | 39.58M |
| December 31, 2015 | 39.36M |
| September 30, 2015 | 35.57M |
| June 30, 2015 | 33.58M |
| March 31, 2015 | 38.33M |
| December 31, 2014 | 43.96M |
| September 30, 2014 | 41.46M |
| June 30, 2014 | 37.91M |
| March 31, 2014 | 40.34M |
| December 31, 2013 | 43.79M |
| September 30, 2013 | 34.34M |
| June 30, 2013 | 33.64M |
| March 31, 2013 | 34.30M |
| December 31, 2012 | 32.21M |
| September 30, 2012 | 31.01M |
| June 30, 2012 | 30.62M |
| March 31, 2012 | 28.64M |
| December 31, 2011 | 32.81M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
31.82M
Minimum
Jun 2020
54.72M
Maximum
Mar 2023
44.77M
Average
46.36M
Median
Research and Development Expense (Quarterly) Benchmarks
| MoonLake Immunotherapeutics | 13.01M |
| LENZ Therapeutics Inc | 10.54M |
| Thermo Fisher Scientific Inc | 331.00M |
| uniQure NV | 40.69M |
| ProQR Therapeutics NV | 10.08M |